CasLoc logo
All Cases PTAB Litigations UPC Oppositions

OSI Pharmaceuticals LLC v. Roxane Laboratories Inc.

1:12-cv-00465

Overview

Case Number 1:12-cv-00465
Filing Date 2012-04-13
Status Terminated
Termination Date 2013-09-16
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Roxane Laboratories Inc. Operating Company

Represented By

3 Attorneys Listed

Marta E. Gross

Email: mgross@goodwinprocter.com

Keith A. Zullow

Email: kzullow@goodwinlaw.com

Richard K. Herrmann

ADDRESS EXPIRED / UNKNOWN

Tel: +1 (302) 888-6800

ADDRESS EXPIRED / UNKNOWN, (302) 888-6800

Plaintiff

Genentech Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Pfizer Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

OSI Pharmaceuticals LLC Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials 1 proceeding
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Parallel Proceedings Across Jurisdictions (4 found):
PTAB: 1 U.S. Courts: 3
USPTO PTAB Trial 2016-06-28
IPR2016-01284

Apotex, Inc. et al. v. OSI Pharmaceuticals, LLC et al.

U.S. Continuation Sibling (6900221)
Status: Final Written Decision
U.S. District Court 2015-09-02
1:15-cv-00772

OSI Pharmaceuticals, LLC v. Apotex Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-12-07
1:12-cv-01669

OSI Pharmaceuticals LLC v. Roxane Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-05-23
1:12-cv-00644

OSI Pharmaceuticals LLC v. Roxane Laboratories INC.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
USRE41065
Alkynl and azido-substituted 4-anilinoquinazolines
Filed: 2008-02-27
Issued: 2009-12-29
Expired (Term Ended)
Expires: 2018-11-08
US6900221
Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
Filed: 2000-11-09
Issued: 2005-05-31
Expired (Term Ended)
Expires: 2020-11-09
US7087613
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
Filed: 2004-11-18
Issued: 2006-08-08
Expired (Term Ended)
Expires: 2024-11-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked (3.5, 7.5, 11.5 Years).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

6

Dispositive

0

Granted

0

Denied

0

Pending / Review

3

Motions by Category

Procedural / Extension Motion 4 Claim Construction / Markman Filing 2

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
Letter to The Honorable Sue L. Robinson from Jack B. Blumenfeld regarding Joint Claim Construction Statement and Claim Charts. (Blumenfeld, Jack) (Entered: 04/1...
Entry #26 • 2013-04-17 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 25 STIPULATION TO EXTEND TIME for the parties to exchange lists of claim terms which they believe need construction to April 8, 2013. Signed by J...
Entry #β€” • 2013-03-27
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for the parties to exchange lists of claim terms which they believe need construction to April 8, 2013 - filed by Genentech Inc., OSI...
Entry #25 • 2013-03-25 Document →
Claim Construction / Markman Filing Pending
SO ORDERED, re 16 SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. ( Joinder of Parties due by 3/29/2013., Amended Plea...
Entry #β€” • 2012-07-03
Procedural / Extension Motion Pending
SO ORDERED, re 7 STIPULATION TO EXTEND TIME to move, answer, or otherwise respond to the Complaint to June 4, 2012 filed by Genentech Inc., Roxane Laboratories ...
Entry #β€” • 2012-05-03
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to move, answer, or otherwise respond to the Complaint to June 4, 2012 - filed by Genentech Inc., OSI Pharmaceuticals LLC, Pfizer Inc...
Entry #7 • 2012-05-02 Document →

Docket Entries

(43 total)
Pleading / Complaint

COMPLAINT filed against Roxane Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 311-1055925.) - filed by Pfizer Inc., OSI Pharmaceuticals LLC, Genentech Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(dmp, ) (Entered: 04/13/2012)

Entry #1 • 2012-04-13
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (dmp, ) (Entered: 04/13/2012)

Entry #2 • 2012-04-13
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 03/12/2012. Date of Expiration of Patent: 11/08/2018 for RE41,065, 11/09/2020 for 6,900,221, 11/09/2020 for 7,087,613.Thirty Month Stay Deadline: 9/12/2014. (dmp, ) (Entered: 04/13/2012)

Entry #3 • 2012-04-13
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE41,065 E; 6,900,221 B1; 7,087,613 B2;. (dmp, ) (Entered: 04/13/2012)

Entry #4 • 2012-04-13
1

Disclosure Statement pursuant to Rule 7.1 filed by Genentech Inc., OSI Pharmaceuticals LLC, Pfizer Inc. identifying Corporate Parent Roche Holdings Inc., Other Affiliate Novartis AG, Other Affiliate Roche Holdings Ltd. for Genentech Inc.; Corporate Parent Astellas US LLC, Other Affiliate Astellas US Holding Inc., Other Affiliate Astellas Pharma Inc. for OSI Pharmaceuticals LLC. (dmp, ) (Entered: 04/13/2012)

Entry #5 • 2012-04-13
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc